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Abstract
Recently  published  detailed  X-ray  structures  of  the  three  common  forms,  A,  B  and   C,   of
Oligomycin, including absolute configurations, have been employed in order  to  investigate  their
binding  to  ATP  synthase.  The  X-ray  studies   revealed   regions   with   differences   in   three-
dimensional structure and hydrogen bonding propensity between the Oligomycins, which  may  in
turn be associated with their potential to bind to sites on the ATP synthase molecule. In  the  x-ray
structure of Oligomycin A most of the potential H-bond donors and acceptors are employed in the
formation  of  four  intramolecular  interactions.  The  three  groups  OH(24),  OH(28)  and  O(36)
participate in intermolecular H-bonds. In the x-ray  structure  of  Oligomycin  B  and  C  only  one
intramolecular H-bond is formed. The  six  groups  OH(2),  O(7),  OH(24),  OH(25),  OH(28)  and
O(36 participate in intermolecular H-bonds in Oligomycin B  and  four  OH(2),  OH(24),  OH(28)
and O(36) in Oligomycin C. Therefore the x-ray data suggest  that  Form  A  is  thus  possibly  the
most stable,  and  form  B  the  most  versatile  with  respect  to  receptor  binding.  Computational
docking studies carried out in MOE using the x-ray structures above and  an  homology  model  of
the F0 domain of the ATP synthase from E. Coli (also built using MOE), were  used  to  derive  an
induced fit pocket.
1. Introduction
Oligomycin   is   an   antibiotic   that   occurs   in   the   gram   positive    bacterium    Strepomyces
diastatochromogenes.  It  is  known  (Lardy,  1980)  to  act  as  a   potent   inhibitor   of   oxidative
phosphorylation and, as a specific inhibitor, acting at the site of coupling between  respiration  and
phosphorylation,  Oligomycin  is  used  extensively  in  experiments  designed,   for   example,   to
investigate the mechanisms  of  processes  in  mitochondria  (  Fossati,  Moulding,  Spiller,  et  al.,
2003)   and  studies  involving  Oligomycin-sensitive  ATP  synthase   (   Altamura,   Capitanio,   ,
Bonnefoy, et al., 1996 and  Cho, Balasubramanyam, Chernaya, et  al.,  1997).   The  three  distinct
forms, Oligomycin A, B and C, differ from each other chemically only in one or two  substituents.
Experiments using Oligomycin as a probe, do not usually attempt to distinguish between  possible
differences from using a particular type of Oligomycin, and often use the unrefined mixture of  all
three. Detailed X-ray structures for all three  Oligmycins  have  been  reported  recently  including
their absolute configurations (Potter and Palmer, 2008).  Enzymes  known  as  ATP  synthases  are
complex multi-subunited  protein  structures  that  can  synthesize  adenosine  triphosphate  (ATP)
from adenosine diphosphate (ADP) and inorganic phosphate. In mitochondria,  the  ATP  synthase
molecule can be visualized as having a major domain, F1, outside the cell membrane, and a minor
domain, FO, embedded within the membrane. FO (written as a subscript  "O",  not  "zero")  derives
its name from being the Oligomycin binding domain and is also known as OSCP (the  oligomycin
sensitivity conferal protein). The F1  domain,  diameter  9  nm,  can  be  seen  in  the  transmission
electron microscope by negative staining as first observed at least  partially  by  Fernandez-Moran
(Fernandez-Moran, 1962). The antibiotic Oligomycin binds to  and  inhibits  ATP  synthase.  ATP
synthase is found in the mitochondria of cells, its function is to extract energy  via  the  conversion
of adenosine diphosphate (ADP) into adenosine triphosphate (ATP). The general reaction  scheme
is:
ADP + Pi (Phosphate) ? ATP
The mechanism by which this conversion takes place is unique  as  it  employs  a  biological  rotor
driven by the passage of protons through a membrane.
The ATP Synthase complex is constructed of numerous subunits  that  work  together  (Figure  1).
The ? and ? units contain the catalytic sites that carry  out  the  reaction  between  ADP  and  ATP;
they are arranged in alternating ? and ?  units totalling three of each. In the centre of this construct
is the central stalk which consists of the ? unit with (in the case  of  mitochondrial  ATP  synthase)
? and ? units  at  the  “foot”,  the  arrangement  is  slightly  different  in  the  case  of  E.  coli  ATP
synthase. This “foot” is  in  contact  with  the  c-ring,  made  up  of  9  –  12  c  subunits  in  a  ring
formation. The c-ring and central stalk rotate within the ? and  ?  construct  in  order  to  cause  the
conformational changes required for catalytic activity. This rotation is a result of  proton  transport
facilitated by the a-subunit that allows access to a proton (H+), this binds to a hydrophilic  channel
between the c-ring and the a-subunit, the ring moves round exposing  an  empty  site  for  the  next
H+. The bound H+ stays bound to the c-ring  until  it  has  come  nearly  full  circle  back  to  the  a
subunit where it enters a second hydrophilic channel that opens  inside,  whereupon  it  is  released
leaving an empty site for the next H+ (von Glehn, Norrestam, et al., 1972). The b subunit is attached to
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the a-unit along with the OSCP (oligomycin sensitivity conferral protein) or ?  (depending  on  the
system see Figure 1) that binds to the top of the ? ? construct. The  top  of  the  structure  (?  ?  and
? complex) is known as the F1 domain and  the  c-ring,  the  a-unit  and  the  other  transmembrane
units are known as the Fo (o for oligomycin) domain. The Fo domain is thought  to  be  where  the
antibiotic oligomycin binds to inhibit the production of  ATP.  There  are  numerous  examples  of
mutational studies being carried  out  that  reveal  a  possible  binding  site  for  oligomycin  at  the
interface between the a subunit and the  c-ring  (Fernandez-Moran,  1962  and  Abrahams,  Leslie,
Lutter  and Walker, 1994). The crystal structure of  the  F1  catalytic-domain  of  ATP  synthase  is
known (Abrahams, Leslie, Lutter, and Walker, 1994) and is largely consistent with Boyer’s rotary-
catalysis model (Boyer, 1993). As oligomycin  contains  a  28  membered  ring  and  therefore  has
numerous conformational possibilities, we have used the actual  experimentally  determined  x-ray
structures of the three forms of oligomycin as the starting point for our docking studies. The study
reported  here  locates  and  characterises  the  Oligomycin  binding  site  in  the  Fo  subunit  of  an
homology model of the ATPase from E.coli, employing the three oligomycin molecular structures
independently.
2. Experimental
21. ATPase Fo Model.
The structure derived from NMR data and provided in the EBI (European Bioinformatics
Institute), PDB entry code 1c17 (Rastogi and Girvin, 1999) does not contain the section with
residues numbered 167-198 in the a-subunit. The full sequence for this subunit was submitted to
the SWISSMODEL homology modeling server (www.expasy.org) this section was included in
the output model. The model provided by SWISSMODEL was superposed onto the coordinates of
the same in 1c17 using MOE ( Chemical Computing Group) and energy minimisation of the three
chains involved in ligand binding was carried out until no bad VDW (van der Waal) contacts were
visible.
2.2 Creation of Pocket for Docking to the ATPase Fo
Owing to  the  lack  of  space  between  the  subunits  thought  to  be  involved  in  the  binding  of
oligomycin, there is the need to create a pocket into which to dock the ligand. A small space at the
desired location was found using Site Finder in MOE  and  dummy  atoms  were  placed  into  this
pocket.  oligomycin  B  was  then  manually  overlaid  onto  these  dummy  atoms  and   a   energy
minimisation was carried out using AMBER99  (Case,  Cheatham,  Darden,  at  al.,  2005)  on  the
three chains involved in binding, the two c subunits and  the  a  subunit.  The  backbone  atoms  of
these chains were tethered with a default weight of 100 in order to keep the structural  integrity  of
the overall structure, and a gradient of 0.1 was applied to the calculation. The energy minimisation
was  carried  out  twice  more  after  termination   of   the   calculation   (gradients   0.1   and   0.05
respectively) to eliminate disagreeable geometries. These included unreasonable bond lengths and
the macrocyclic ring of the ligand positioning itself around a helix (remedied by  moving  the  ring
atoms back to the desired side of the helix). This resulted in a converged energy  minimisation.  In
order to introduce diversity into the shape of the binding site and to allow for  the  other  forms  of
oligomycin, oligomycin A was overlaid on  to  the  coordinates  of  the  energy  minimised  ligand
within the pocket; and a further energy minimisation was  performed  using  the  conditions  stated
above.
2.3 Docking of Oligomycin.
Site  Finder  in  MOE  was  used  to  place  dummy  atoms  into  the  pocket.  The  algorithm   was
instructed to use the receptor atoms as the receptor, the dummy  atoms  as  the  site  into  which  to
dock the ligand and the selected atoms within the environment  to  be  the  ligand.  The  placement
method used was the Alpha  Triangle  method  (in  MOE)  and  the  scoring  was  the  London  dG
method. Each run was instructed to retain 200 docked conformations as a cut-off unless it  reached
the timeout limit of 600 seconds.
Owing to the uncertain nature of the aforementioned bond geometry within oligomycin A,  it  was
decided to dock two forms: one where an extra hydrogen was added, creating a form with a  single
bond (A) and a second where it was constrained as a double bond (A=). All forms (A, A=,  B  and
C) were docked to the site according to this method and conditions.
4 3. Results/Discussion.
3.1. X-ray Structures: Discussion.
Figure 2 summarizes the chemical structures of the three forms of  Oligomycin  as  determined  by
the recent structure analyses and the  atom  numbering  used.  ORTEP  (Farrugia,  1997)/Raster3D
(Merrit and Bacon, 1997) corresponding views  of  the  three  molecular  conformations
are shown  in  Figures  3(a,  b  and  c).  Inspection  of  these  diagrams  reveals  subtle  differences
between the three  forms.  As  discussed  below,  whereas  these  differences  are  seemingly  quite
small, their significance may lie in what effect they have on ATPase binding characteristics.
3.1.1 Conformational Variations in the Macrocyclic Structures.
Figure 2  shows  the  common  macrocyclic  chemical  structure  of  the  Oligomycins.  The  X-ray
analyses have revealed minor differences in the overall macrocycle ring  structures  which  can  be
seen in Figures 3(a, b, c). There are  four  chain-like  stretches  in  each  structure  as  described  in
Table 1. Bends occur  at  each  of  the  four  chain  junctions  as  specified  in  Table  2.  The  most
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significant difference in the geometry of the bends in the three forms occurs in Bend 4 which  runs
from C(30 to C(35) and links Chains III and IV. The  torsion  angles  in  this  stretch  are  listed  in
Table 3. The torsion angle about C(33)-C(34)  is  variable,  with  values  of  134.3º  and  135.7º  in
Oligomycins A and B, with a significant change of about 17º to 117.7º in Oligomycin C.
3.1.2 Side Group Orientations.
Figures 3(a, b and c) reveal small differences in some side group orientations.  Further  details  are
shown in  Figures  4(a,b  and  c).  These  differences  are  very  likely  to  be  important  factors  in
determining the binding characteristics essential for understanding the biological activities  of  the
Oligomycins. In the following discussion the term “external” applies to groups facing in a  general
outwards direction ie away from the macrocyclic ring and  “internal”  facing  groups  are  pointing
inwards. External side groups are likely to be exposed and have a high  propensity  for  binding  to
or interacting with a receptor.
CH3 Groups: In Oligomycin A, B and C  two  CH3  groups  are  internal  ie  those  on  C(12)  and
C(27). All other CH3 groups are external.
OH and =O Groups: In Oligomycin A, while the five OH groups are all external, only  two  form
intermolecular H-bonds. There are also four intramolecular OH-bonds, but these are unlikely to be
able to convert to intermolecular and contribute to receptor binding.  These  are  :  (1)  O(2)H---  =
O(9) [in ring X, see Figure 2), stabilizing the R4 side  chain;  (2)  O(25)H----  O(24)H,  stabilizing
bend III; (3) O(28)H --- =O(30) and (4) O(32)H ---  =O(30),  both  stabilizing  bend  IV.  The  two
intermolecular hydrogen bonds are formed by   OH(28) with O(36) and  OH(24)  with  OH  of  the
solvated methanol  [see Table 4a].
In Oligomycin B the situation is different. The five OH groups are all external but only  O(32)H---
=O(30), which again stabilizes bend IV, is the only  intramolecular H-bond formed. The  fact  that
the  other  four  OH  groups  form  intermolecular   hydrogen   bonds   (Table   4b)   suggests   that
Oligomycin B will have potentially more opportunities for OH-bonding to protein  receptors  than
Oligmycin A. Due to the presence of three more intramolecular OH-bonds, Oligomycin A may  be
a much more stable conformation than Oligomycin B or C and less likely to bind to ATPase.
In Oligomycin C there is no R25 OH group (Figure 2). The three OH groups  are  all  external  but
O(32)H--- =O(30) again stabilizes bend IV, and this is the  only   intramolecular  H-bond  formed.
This provides Oligomycin C with three opportunities for OH-bonding to protein  receptors  (Table
4c).
In Oligomycin A, B and C =O(26) is internal, both =O(30) and =O(36)  are  external.  Oligomycin
B has an additional =O(7) on pyranose ring X (Figure 2) and this side group may be  described  as
external and does in fact participate in intermolecular H-bonding.
3.1.3 Hydrogen Bonding
Hydrogen bonding for Oligomycins A, B and C is summarized in Table 4. This  shows  that  there
are two intermolecular H-bonds in the Oligomycin A structure and  four  intramolecular  H-bonds;
there are four intermolecular H-bonds in the Oligomycin B structure, and only one  intramolecular
H-bond; in Oligomycin C there are three intermolecular H-bonds and only one  intramolecular  H-
bond. This suggests that Oligomycin B may have the greatest potential of the three Oligomcins for
receptor binding.
3.1.4 Summary of the H-bonding  in Oligomycins A, B and C.
For the various reasons discussed previously only one intermolecular H-bond i.e. between OH(28)
and O(36), is a consistent feature of these crystal structures.  It  may  be  concluded  therefore  that
both OH(28) and =O(36) are highly exposed on the molecular surface.  OH(2) is  also  exposed  in
Oligomycins B and  C  forming  H-bonds  either  to  solvent  or  symmetry  related  molecules.  In
Oligomycin A OH(2) forms an intramolecular H-bond to O(9) on pyranose ring X. OH(24) is also
exposed forming H-bonds to solvate in A and B and  to  symmetry  related  OH(2)  in  C.  OH(32)
consistently forms a stabilizing intramolecular  H-bond  with  =O(30)  and  both  oxygens  can  be
discounted from binding studies. Apart from the intramolecular H-bond between O(2) and O(9) in
Oligomycin A, pyranose oxygens O(9) and O(14) do not participate in H-bonding interactions and
can be taken to be inaccessible as can =O(26) and –O(37)-. Figures 5(a, b and c) illustrate some of
these aspects of the structures (drawn with ORTEP  (  Farrugia,  1997)/Raster3D  (Merrit  and
Bacon, 1997) in WinGX).
5. Proposed Key Groups for Receptor Binding from X-ray Analysis.
It may  be  concluded  that  the  key  groups  which  are  likely  to  be  involved  in  intermolecular
interactions with protein subunits are: OH(2) [probably only in Oligomycins  B  and  C],  OH(24),
OH(28) and O(36).  The  conclusions  about  OH(28)  and  =O(36)  are  clearly  borne  out  by  the
VMD22 SURFACE ( Humphrey, Dalke, and Schulten, 1996) plots of  the  three  molecules  shown
in Figure 5. Other features and differences  of  the  molecular  structures  discussed  above  can  be
clearly seen by careful inspection of these plots.
5 3.2 Oligomycin/ATPase Docking.
For each of the four types of oligomycin that were docked  the  following  was  recorded  for  each
contact made with the protein (more than one in some cases):
• residue type, number and subunit (subunit according to Figure 6);
• bonding  type  according  to  MOE  (backbone  acceptor/  donor,  H-bond  acceptor/  donor
(sidechain));
• distance between donor and acceptor as calculated by MOE (Å);
• contact point on the ligand according to numbering scheme Figure 7.
In the above example oligomycin C is bound to both a c-subunit via an Asp61 and Asn214  of  the
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a-subunit, both of which are essential for proton transport through the membrane according to  the
literature [38-47].
This suggests a combination of mechanisms by which this antibiotic could act: by binding to these
residues it prevents the proton  binding  to  the  required  residues  and  thus  passage  through  the
membrane. This is compounded by the binding to both the a-subunit, that is stationary  within  the
membrane and the c-subunit; which is part of an oligomeric  arrangement  of  subunits  that  rotate
within the membrane, thereby preventing rotation. The sheer bulk of the  ligand  would  also  be  a
factor here, as it may act  as  a  “stick  in  the  spokes”  preventing  rotation.  The  docking  studies
performed have highlighted contacts to the following residues that are  mentioned  multiple  times
as essential to proton transport through the  membrane:  Asp61  [38-45],  Arg210  [38-43,  46-49],
Asn214 [38, 40, 41, 46, 47] and Gln252 [38-42, 44, 46].
Experimental KI values for oligomycin bound to ATPase  appear  range  quite  widely;  the
only reported values appear to be  for  various  types  of  the  mitochondrial  ATPase  and  not  the
bacterial version. Values range from 0.0065 ?M in Mg2+ ATPase [50] to 26 ?M in  clathrin-coated
vesicles in rat liver [51]. A smaller range was suggested for bovine heart  mitochondria  0.1  –  0.6
?M [52]. The average calculated KI (calculated from ?G) for A  is  9.960E-06  ?M  (Table  5),  this
and all the other values seem to be very low compared with the literature;  however  this  could  be
due to being calculated  under  “perfect”  conditions  with  no  competition  between  the  different
forms and /or solvent.
The average binding  energies  indicate  that  the  B  and  C  forms  bind  better  than  the  A  form,
however the A form dominates as it is in much greater abundance of  concentration  to  the  others
(75:10:8). A comparison of the average binding energies of the  A  and  the  A=,  suggest  that  the
form without the double bond binds better; this could well be due to the restriction of rotation  that
the double bond will introduce, preventing the group interacting with essential residues.
It is also interesting to note that the beginnings  of  a  binding  mode  for  the  ligand  is  becoming
apparent, the same contact  groups  on  the  ligand  have  preferences  for  particular  residues.  For
example the contact 10(A)/ 11(B)/ 9(C) (See Figure.11) out of 69 contacts with residues,  59  were
sidechain  hydrogen  bonded  to  Gln252.  this  would  warrant  further  investigation  after  further
dockings.
4. Conclusions
The X-ray study has shown that, while Oligomycins A, B and C are chemically very  similar,  and
A and B are crystallographically pseudo isomorphous, the small differences that do exist  between
them has significant effects on how they are able to take part in  intermolecular  interactions.  This
information is important for the assessment of  the  receptor  binding  potential  of  Oligomycin  to
sites in the ATP synthase system, and in particular when such assessments  are  being  carried  out
by graphics aided computer simulations. It has been shown that in the case of  Oligomycin  A  two
surface located sites are available for intermolecular binding, while there are  four  in  Oligomycin
B and three in Oligomycin C. These are highlighted in Table 2, counting interactions with  solvent
as possible intermolecular binding sites. This result indicates  that  Oligomycin  B,  with  an  extra
oxygen atom, O(7), available on the surface, may be better  favoured  than  the  A  or  C  form  for
taking part in interactions with protein subunits.
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5. Supplementary material
Crystallographic data (excluding  structure  factors)  for  the  structures  reported  here  have  been
deposited  with  the  Cambridge  Crystallographic  Data   Centre   as   supplementary   publication
numbers CCDC 636099, CCDC 636100 and CCDC 636101. Copies of available  material  can  be
obtained free of charge on application to the Director, CCDC,  12  Union  Road,  Cambridge  CB2
1EZ, UK (email teched@chemcrys.cam.ac.uk)
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Table 1. Chain regions and their conformations in Oligomycins A, B and C.
|      |                  |                         |                  |
|Chain |Region in         |Overall Properties of    |Special Properties|
|      |Structure         |Chain                    |                  |
|      |                  |                         |                  |
|I     |C(36) to C(17)    |Extended conformation    |Kink at O(37)     |
|   II |                  |                         |                  |
|      |C(17) to C(23)    |Extended conformation    |Slightly convex   |
|      |                  |                         |                  |
|III   |C(21) to C(34)    |Gradual clockwise coil   |Most variable     |
|      |                  |                         |section           |
|      |                  |                         |of the three      |
|      |                  |                         |structures        |
|      |                  |                         |                  |
|IV    |C(33) to C(36)    |Fully extended in all    |                  |
|      |                  |four                     |                  |
|      |                  |Structures               |                  |
Table 2. Bend regions and properties in Oligomycins A, B and C.
|     |           |                                |                  |
|Bend |Region in  |Nature of Bend                  |Special Properties|
|     |Structure  |                                |                  |
|     |           |                                |                  |
|1    |Linking    |Twist of -3º about bond         |                  |
|     |chains     |C(35)-C(36)                     |                  |
|     |I and IV   |                                |                  |
|     |           |                                |                  |
|2    |Linking    |Changes in the torsion angles   |                  |
|     |chains     |about bonds C(16)-C(17) and     |                  |
|     |I and II   |C(17)-C(18), from extended on   |                  |
|     |           |either side to approximately    |                  |
|     |           |-60º and 100º respectively      |                  |
|     |           |                                |                  |
|3    |Linking    |Transitions in torsion angles   |                  |
|     |Chains     |about C(21)-C(22) and           |                  |
|     |II and III |C(22)-C(23) from the extended   |                  |
|     |           |mode, to approximately -130º and|                  |
|     |           |-60º respectively.              |                  |
|     |           |                                |C(33)-C(34) is    |
|4    |Linking    |Changes in torsion angles about |highly variable   |
|     |chains     |C(32)-C33) and C(33)-C(34) from |with values of    |
|     |IIIand IV  |extended mode. on either side.  |134.3, 135.7 and  |
|     |           |C(32)-C(33) has values around   |117.7º in         |
|     |           |-55º in all three structures.   |Oligomycins A, B  |
|     |           |                                |and C             |
|     |           |                                |respectively.     |
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Table 3. Torsion angles in the variable Bend 4
|Oligomyci|C30-C31-C32-C3|C31-C32-C33-C3|C32-C33-C34-C3|C33-C34-C35-C36 |
|n        |3             |4             |5             |                |
|A        |174           |-56           |134           |176             |
|B        |176           |-59           |136           |174             |
|C        |177           |-52           |118           |177             |
Table  4a.  Hydrogen  bonds  in  Oligomycin  A  [Å  and  °]   –   2   intermolecular   involving   3
groups OH(24), OH(28) and O(36) ; 4 intramolecular.
|D-H……A            |D(D…A)            |<DHA              |     Type        |
|O28-H28A…=O36     |2.892             |129.8             |Intermolecular   |
|O24-H24…O60*      |2.647             |  98.4            |Intermolecular   |
|                  |                  |                  |[*solvent]       |
|O2-H2…O9          |3.042             |134.6             |Intramolecular   |
|O25-H25…O24       |2.586             |106.3             |Intramolecular   |
|O28-H28...=O30    |3.309             | 140.2            |Intramolecular   |
|O32-H32...=O30    |2.788             | 119.1            |Intramolecular   |
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Table  4b.  Hydrogen  bonds  in  Oligomycin  B  [Å  and  °]  -   4   Intermolecular,   involving   6
groups OH(2), O(7), OH(24), OH(25), OH(28) and O(36); 1 Intramolecular
|D-H……A            |D(D…A)            |<DHA              |     Type        |
|O28-H28A…O36      |2.809             |129.8             |Intermolecular   |
|O25-H25…O7        |2.804             |179.8             |Intermolecular   |
|O24-H24…O611*     |2.724             |179.5             |Intermolecular   |
|                  |                  |                  |[*solvent]       |
|O2-H2A…O612*      |2.899             |110.5             |Intermolecular   |
|                  |                  |                  |[*solvent]       |
|O32-H32...O30     |2.719             | 121.1            |Intramolecular   |
Table  4c.  Hydrogen  bonds  in  Oligomycin  C  [Å  and  °]  –   3   Intermolecular,   involving   4
groups OH(2), OH(24), OH(28) and O(36); 1 Intramolecular
|D-H……A            |D(D…A)            |<DHA              |Type              |
|O28-H28A…O36      |2.902             |142.8             |Intermolecular    |
|O2-H2A…O24        |3.424             |178.2             |Intermolecular    |
|O24-H24A…O2       |3.424             |178.3             |Intermolecular    |
|O32-H32A…O30      |2.809             |142.0             |Intramolecular    |
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Table 5: Numbers of docked conformations with contacts to the protein
|Oligomyci|Number of Bound |Total number  |
|n  type: |conformations to|of contacts:  |
|         |date            |              |
|A        |68              |102           |
|A=       |33              |37            |
|B        |58              |85            |
|C        |149             |247           |
Table 6:Top 5 contacted residues with % of total contacts.
|        |Top 5 Residue contacts:                                                    |
|Oligomycin  |Residue    |% of     |Residue   |% of total|
|type:       |           |total    |          |contacts  |
|            |           |contacts |          |          |
|A           |-2.4       |2.8      |9.960E-06 |4.638E-08 |
|A=          |-1.4       |2.6      |9.976E-06 |4.321E-08 |
|B           |-3.9       |2.6      |9.934E-06 |4.402E-08 |
|C           |-4.4       |3.3      |9.926E-06 |5.522E-08 |
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Figure Captions:
Figure 1: Subunit arrangement for ATP Synthases from Mitochondria vs E. coli.
Figure 2. Chemical structures of Oligomycins A, B and C: crystallographic numbering, R  groups,
solvation charactistics, chain stretches and bends.
Figure 3(a,b,c). Molecular conformations  of  Oligomycins  A,  B  and  C  respectively.  The  view
selected displays the most open projection of the molecule and corresponds approximately to  that
of Figure 1 (drawn with ORTEP16/Raster17 as implemented in WinGX13).
Figure 4(a,b,c). ORTEP16/Raster17 views of Oligomycins A, B and C respectively showing groups
which form intermolecular hydrogen  bonds  (*)  in  the  crystal  structures,  and  which  might  be
involved in receptor binding. (a) Oligomycin A: groups involved are OH(24), OH(28) and  O(36).
OH(2) forms an intramolecular hydrogen bond to O(9) and is probably not  available  for  receptor
binding. (b) Oligomycin B: groups involved  are  OH(2),  O(7)  [present  only  in  Oligomycin  B],
OH(24), OH(25), OH(28) and O(36).  (c)  Oligomycin  C:  groups  involved  are  OH(2),  OH(24),
OH(28) and O(36).
Figure 5. Surface representations of Oligomycins A, B and  C  (VMD22  SURFACE).  Two  views
are shown in each case. View 1 (Front  View)  corresponds  approximately  to  Figure  2.  View  2
(Back View) is as seen from the back of View 1. * Indicates group forming  an  intermolecular  H-
bond.
5(a1) Oligomycin A Front View:  OH(25)  forms  an  intramolecular  hydrogen  bond  with  O(24)
which could exclude both from receptor binding.
5(a2) Oligomycin A Back View: O(26) is buried and unlikely to be able  to  take  part  in  receptor
binding.
5(a3) Olgomycin A Lower View showing O(36) exposed and a  potential  contributor  to  receptor
binding.
5(a4) Oligomycin A Top View: OH(25) is seen in this view to be highly exposed.
5(b1) Oligomycin B Front View: There are five active groups in this surface view  of  Oligomycin
B, compared to two in Oligomicin A and zero in Oligomycin C. This  suggests  that  Oligomcin  B
has greater potential for receptor binding than A or C.
5(b2) Oligomycin A Back View: O(26) is buried and unlikely to be able  to  take  part  in  receptor
biding.
5(b3) Olgomycin B Lower View showing OH(2) and C(36) exposed and  potential contributors to
receptor binding.
5(b4) Oligomycin B Top View:
5(c1) Oligomycin C Front View: This  surface  view  has  three  potential  receptor  binding  sites.
OH(24) appears to be partially buried but does in fact  participate  in  an  intermolecular  hydrogen
bond. In addition OH(2) is quite exposed in the structure but out of this view.
5(c2) Oligomycin C Back View: O(26) is buried and unlikely to be able  to  take  part  in  receptor
biding.
5(c(3) Olgomycin C Lower View showing OH(2) exposed and a potential contributor  to  receptor
binding.
5(b4) Oligomycin B Top View:
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Figure 1: Subunit arrangement for ATP Synthases from Mitochondria vs E. coli. (Image
modified from http://rpi.edu/dept/bcbp/molbiochem/MBWeb/mb1/part2/f1fo.htm accurate
04/02/2008)
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                                                Figure 3(a).
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                                                  Figure 3(b).
                                                          Figure 3(c).
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Figure 4(a)
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Figure 4(b)
Figure 4(c)
                                                     Figure 5a(1)
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                                                            Figure 5a(2)
                                                            Figure 5a(3)
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                                            Figure 5b(1)
                                                        Figure 5b(2)
                                                         Figure 5b(3)
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                                            Figure 5c(1)
                                                      Figure 5c(2)
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                                                    Figure 5c(3)
Figure 6. Assignment of subunit identification.
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Figure7. Numbering scheme for ligand contact points.
Figure 9 Stereo view example of docking: oligomycin C docked @ -7.8kcal/mol, KI: 9.9E-06
?M
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Figure 12. Ligand interaction diagram of oligomycin C / ATPase.
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